Atul Pande serves as Executive at Axovant Gene Therapies Ltd., where they oversee executive responsibilities. Since joining the company, Atul Pande has executed 59 insider transactions totaling $8.2M, demonstrating a bearish approach to their equity position. Their most recent transaction on Aug 12, 2020 involved selling 5,000 shares valued at $425.0K.
Atul Pande currently holds 94,413 shares of Axovant Gene Therapies Ltd. (AXGT), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Atul Pande has been a net seller of AXGT stock. They have purchased $210.0K and sold $8.0M worth of shares.
Atul Pande's most recent insider trade was on Aug 12, 2020, when they sold 5,000 shares at $85.00 per share.
Get notified when new Form 4 filings are submitted
| $95.43 |
| Discretionary |
| Jul 13, 2020 | KRTX | $14.6K | Option Exercise | 5,000 | $2.92 | Discretionary |
| Jul 8, 2020 | AXGT | $27.3K | Purchase | 10,000 | $2.73 | Discretionary |
| Jun 12, 2020 | KRTX | $466.4K | Sale | 5,000 | $93.27 | Discretionary |
| Jun 12, 2020 | KRTX | $14.6K | Option Exercise | 5,000 | $2.92 | Discretionary |
| May 15, 2020 | IMVT | $0 | Award | 24,700 | $N/A | Discretionary |
| Mar 16, 2020 | AXGT | $17.8K | Purchase | 10,000 | $1.78 | Discretionary |
| Jun 14, 2019 | AXGT | $17.6K | Purchase | 3,370 | $5.22 | Discretionary |